Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Trial Profile

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telaglenastat (Primary) ; Cabozantinib; Docetaxel; Erlotinib; Everolimus; Paclitaxel
  • Indications Advanced breast cancer; Gastrointestinal stromal tumours; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 16 Feb 2019 Results of CB-839 + Cabo cohort evaluating the safety, efficacy, and recommended Phase 2 dose (RP2D) presented at the 2019 Genitourinary Cancers Symposium.
    • 16 Feb 2019 According to a Calithera Biosciences media release, data will be presented at the American Society of Clinical Oncology Genitourinary Cancer (ASCO GU) Symposium 2019.
    • 18 Jul 2018 Planned End Date changed from 1 Sep 2017 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top